Acta NaturaeActa NaturaeActa Naturae2075-8251Acta Naturae Ltd2745710.32607/actanaturae.27457Research ArticlesЭкспериментальные статьиResearch ArticleInhibition of HBV replication by a fully humanized neutralizing antibody in vivo and in vitroInhibition of HBV replication by a fully humanized neutralizing antibody in vivo and in vitroZhangZhipeng
China

Laboratory of Pharmaceutical Engineering, School of Life Science and Health Engineering

zhipengzhang2009@163.comMaYanqinMaYanqin
China
zhipengzhang2009@163.comHeYan
China
zhipengzhang2009@163.comWangDong
China
zhipengzhang2009@163.comSongHuaien
China
zhipengzhang2009@163.comYueKun
China
zhipengzhang2009@163.comZhangXiaomei
China

Laboratory of Pharmaceutical Engineering, School of Life Science and Health Engineering

zhipengzhang2009@163.comJiangnan UniversitySuzhou Hepa Thera Biopharmaceutical Co., Ltd.22042025171971051107202428012025Copyright ©; 2025, Zhang Z., Ma Y., He Y., Wang D., Song H., Yue K., Zhang X.Copyright ©; 2025, Zhang Z., Ma Y., He Y., Wang D., Song H., Yue K., Zhang X.2025Zhang Z., Ma Y., He Y., Wang D., Song H., Yue K., Zhang X.Zhang Z., Ma Y., He Y., Wang D., Song H., Yue K., Zhang X.https://creativecommons.org/licenses/by/4.0https://actanaturae.ru/2075-8251/article/view/27457

Neutralizing antibodies are capable of specifically binding to the HBsAg virus, thereby preventing HBV infection and subsequently reducing viral antigen load in both the liver and systemic circulation. This has significant implications for restoring the postnatal immune function. By utilizing the phage antibody library technology, we successfully screened a fully humanized neutralizing antibody targeting the hepatitis B surface antigen. The antiviral activity was assessed in primary human hepatocytes (PHHs) by determining the EC50 values for HBeAg and HBsAg biomarkers in HBV types B, C, and D; no cytotoxicity was observed within the tested concentration range. Furthermore, HT-102 exhibited no ADCC effect but displayed a weak CDC effect along with a dose-dependent response. We established an AAV/HBV mouse model and observed significant dose-dependent reduction in HBsAg and HBV DNA levels for both the medium-dose and high-dose groups. The immunohistochemical staining data showed dose-dependent reduction in HBsAg expression in the liver, with high-dose group exhibiting minimal positive expression. Finally, a mild immune response was induced, while reducing the burden of antigen–antibody complexes circulating within the system. Consequently, strain on the patient’s immune system was alleviated by effectively slowing down CD8+T lymphocyte depletion, and functional cure was ultimately achieved as intended.

Neutralizing antibodies are capable of specifically binding to the HBsAg virus, thereby preventing HBV infection and subsequently reducing viral antigen load in both the liver and systemic circulation. This has significant implications for restoring the postnatal immune function. By utilizing the phage antibody library technology, we successfully screened a fully humanized neutralizing antibody targeting the hepatitis B surface antigen. The antiviral activity was assessed in primary human hepatocytes (PHHs) by determining the EC50 values for HBeAg and HBsAg biomarkers in HBV types B, C, and D; no cytotoxicity was observed within the tested concentration range. Furthermore, HT-102 exhibited no ADCC effect but displayed a weak CDC effect along with a dose-dependent response. We established an AAV/HBV mouse model and observed significant dose-dependent reduction in HBsAg and HBV DNA levels for both the medium-dose and high-dose groups. The immunohistochemical staining data showed dose-dependent reduction in HBsAg expression in the liver, with high-dose group exhibiting minimal positive expression. Finally, a mild immune response was induced, while reducing the burden of antigen–antibody complexes circulating within the system. Consequently, strain on the patient’s immune system was alleviated by effectively slowing down CD8+T lymphocyte depletion, and functional cure was ultimately achieved as intended.

Neutralizing antibodyCDC effectHBsAgNeutralizing antibodyCDC effectHBsAgLiang T.J. // Hepatology. 2009. V. 49. P. S13–S21.Papatheodoridi M., Tampaki M., Lok A.S., Papatheodoridis G.V. // Hepatology. 2022. V. 75. № 5. P. 1257–1274. doi: 10.1002/hep.32241Orlando R., Foggia M., Maraolo A.E., Mascolo S., Palmiero G., Tambaro O. // Eur. J. Clin. Microbiol. Infect. Dis. 2015. V. 34. № 6. P. 1059–1070.Kato T., Akari H. // Uirusu. 2023. V. 72. № 2. P. 149–158.Veronese P., Dodi I., Esposito S., Indolfi G. // World J. Gastroenterol. 2021. V. 27. № 26. P. 4182–4193.Hsu Y.C., Huang D.Q., Nguyen M.H. // Nat. Rev. Gastroenterol. Hepatol. 2023. V. 20. № 8. P. 524–537.Wu C.R., Kim H.J., Sun C.P., Chung C.Y., Lin Y.Y., Tao M.H., Kim J.H., Chen D.S., Chen P.J. // Hepatology. 2022. V. 76. P. 207–219.Sun L., Lu X., Li Ch., Wang M., Liu Q., Li Z., Hu X., Li J., Liu F., Li Q., et al. // PLoS One. 2009. V. 4. https://doi.org/10.1371/journal.pone.0005476Kashyap A.K., Steel J., Oner A.F., Dillon M.A., Swale R.E., Wall K.M., Perry K.J., Faynboym A., Ilhan M., Horowitz M., et al. // Proc. Natl. Acad. Sci. USA. 2008. V. 105. P. 5986–5991.Barbas C.F. 3rd, Kang A.S., Lerner R.A., Benkovic S.J. // Proc. Natl. Acad. Sci. USA. 1991. V. 88. P. 7978–7982.Burm R., van Houtte F., Verhoye L., Mesalam A.A., Ciesek S., Roingeard P., Wedemeyer H., Leroux-Roels G., Meuleman P. // JHEP Rep. 2022. V. 5. № 3. P. 100646. doi: 10.1016/j.jhepr.2022.100646Zhang H., Itoh Y., Suzuki T., Ihara K., Tanaka T., Haga S., Enatsu H., Yumiya M., Kimura M., Takada A., et al. // Microbiol. Immunol. 2022. V. 66. P. 179–192. https://onlinelibrary.wiley.com/doi/full/10.1111/1348-0421.12964Yue M., Nie M., Huang X., Zhang T., Zhao Q. // Chin. J. Microbiol. Immunol. 2021. V. 41. P. 805–810. https://rs.yiigle.com/CN115399202004/1340647.htmYang D., Liu L., Zhu D., Peng H., Su L., Fu Y.X., Zhang L. // Cell. Mol. Immunol. 2013. V. 11. P. 71–78.Donkers J.M., Appelman M.D., van de Graaf S.F.J. // JHEP Rep. 2019. V. 1. № 4. P. 278–285.Guo H., Urban S., Wang W. // Front. Microbiol. 2023. V. 14. P. 1169770.Hehle V., Beretta M., Bourgine M., Ait-Goughoulte M., Planchais C., Morisse S., Vesin B., Lorin V., Hieu T., Stauffer A., et al. // J. Exp. Med. 2020 V. 217. № 10. e20200840. doi: 10.1084/jem.20200840Golay J., Manganini M., Facchinetti V., Gramigna R., Broady R., Borleri G., Rambaldi A., Introna M. // Haematologica. 2003. V. 88. № 9. P. 1002–1012.Smith M.R. // Oncogene. 2003. V. 22. № 47. P. 7359–7368.Yang D., Liu L., Zhu D., Peng H., Su L., Fu Y.X., Zhang L. // Cell. Mol. Immunol. 2014. V. 11. № 1. P. 71–78.He Z., Chen J., Wang J., Xu L., Zhou Z., Chen M., Zhang Y., Shi M. // Eur. J. Gastroenterol. Hepatol. 2021. V. 33. № 1. P. 76–82.Song Z., Lin S., Wu X., Ren X., Wu Y., Wen H., Qian B., Lin H., Huang Y., Zhao C., et al. // Hepatol Int. 2023. V. 17. № 5. P. 1300–1317. https://pubmed.ncbi.nlm.nih.gov/37368186/Qi R., Fu R., Lei X., He J., Jiang Y., Zhang L., Wu Y., Wang S., Guo X., Chen F., et al. // J. Hepatol. 2024. V. 80. № 5. P. 714–729. https://pubmed.ncbi.nlm.nih.gov/38336348/Zhang Y.M., Yang Y.D., Jia H.Y., Zeng L.Y., Yu W., Zhou N., Li LJ. // World J. Gastroenterol. 2014. V. 20. № 15. P. 4407–4413.Burm R., van Houtte F., Verhoye L., Mesalam A.A., Ciesek S., Roingeard P., Wedemeyer H., Leroux-Roels G., Meuleman P. // JHEP Reports. 2023. V. 5. № 3. 100646. doi: 10.1016/j.jhepr.2022.100646Lempp F.A., Vincenzetti L., Volz T., Guarino B., Benigni F., Rosen L.E., Zatta F., Bianchi S., Lombardo G., Jaconi S., et al. // American Association for the Study of Liver Diseases (AASLD). Hepatology. 2021. V. 74. P. 513A–514A.Dingman R., Balu-Iyer S.V. // J. Pharm. Sci. 2019. V. 108. № 5. P. 1637–1654. https://pubmed.ncbi.nlm.nih.gov/30599169/Vaisman-Mentesh A., Gutierrez-Gonzalez M., DeKosky B.J., Wine Y. // Front. Immunol. 2020. V. 11. P. 1951. doi: 10.3389/fimmu.2020.01951Lazar G.A., Desjarlais J.R., Jacinto J., Karki S., Hammond P.W. // Mol. Immunol. 2007. V. 44. № 8. P. 1986–1998.Agarwal K., Yuen M.F., Wedemeyer H., Cloutier D., Shen L., Arizpe A., Pang P.S., Tay C., Gupta S.V., Cathcart A.L., et al. // EASL International Liver Congress. 2021. https://www.natap.org/2021/EASL/EASL_43.htm